Abstract: A selfemulsifiable formulation comprising a lipophilic system consisting of a medium chain triglyceride of caprylic acid and capric acid, and of labrasol, wherein labrasol also serves as a surfactant, which is combined with other selected surfactants, like cremophore RH 40 and/or polysorbate 80 and wherein the formulation also comprises immunosuppression agent, essentially cyclosporine, hydrophilic agent preferably ethanol, antioxidant preferably alpha-tocopherol and preservative preferably benzyl alcohol. The formulation is prepared by dissolving immunosuppression agent in hydrophilic agent followed by entrapping with lipophilic agent and subsequent treatment with surfactants, preservative and anioxidant.

Abstract: The present invention relates to a composition or article containing at least one oxidizing agent and at least one reducing agent, wherein at least one of the at least one reducing agent is a depilatory agent, the equivalent ratio of the at least one oxidizing agent to the at least one reducing agent is less than 1:1, and the article is exothermic when wet with water, and the use thereof to remove hair from the skin.

Abstract: Pharmaceutical formulations comprise a mono- or di-aminopyridine active agent for administration on a once- or twice-daily basis for use in the treatment of neurological diseases, in particular multiple sclerosis and Alzheimer's disease. The formulations, which are suitable for oral or percutaneous administration of the active agent, include the active agent in a carrier effective to permit release of the mono- or di-aminopyridine at a rate allowing controlled absorption thereof over, on the average, not less than a 12 hour period and at a rate sufficient to achieve therapeutically effective blood levels over a period of 12-24 hours following administration.

Abstract: A compound represented by the following formula: ##STR1## wherein R is a C.sub.3 -C.sub.24 olefinically unsaturated organic radical having functionality which renders the nitrogen atom electron deficient, the olefinic unsaturation functionality being polymerizable,R.sup.1 is hydrogen or a C.sub.1 -C.sub.4 alkyl radical, orR and R.sup.1 together with the nitrogen atom can form an olefinically unsaturated 5 to 7-member ring which has functionality that renders the nitrogen atom electron deficient and the olefinic unsaturation functionality is polymerizable,R.sup.2 and R.sup.3 are hydrogen, a C.sub.1 -C.sub.4 alkyl or acyl radical, orR.sup.2 and R.sup.3 together are a C.sub.2 -C.sub.4 alkylene group,R.sup.4 is hydrogen or a C.sub.1 -C.sub.4 alkyl, acyl, ester, amide or acid group, andn is an integer from 1 to 10, provided n is not 1 when R is (meth)acryloyl, R.sup.2 and R.sup.3 are methyl and R.sup.1 and R.sup.4 are hydrogen.Under acidic conditions the above compounds in which R.sup.

Abstract: The cutaneous atrophy associated with the use of steroids topically can be ameliorated using salts of certain .alpha.-hydroxyacids.

Abstract: An alkali metal monoalkylphosphate having a saturated or unsaturated straight-chain or branched hydrocarbon group having from 8 to 32 carbon atoms is described; also described is a process for preparing particles of said alkali metal zinc monoalkylphosphate and cosmetics containing said particles.

Abstract: A buoyant controlled release pharmaceutical powder formulation is provided which may be filled into capsules and releases a pharmaceutical of a basic character at a controlled rate regardless of the pH of the environment, which formulation includes a basic pharmaceutical, up to about 45% by weight of a pH dependent polymer which is a salt of alginic acid, such as sodium alginate, up to about 35% by weight of a pH-independent hydrocarbon gelling agent having a viscosity of up to about 100,000 centipoises in 2% solution at 20.degree. C. and excipients.

Abstract: Disclosed is a biocompatible, thromboresistant substance useful for implantable and extracorpeoreal devices in contact with the vascular system, and methods for producing the same. The biocompatible, thromboresistant substance comprises a synthetic, biocompatible material, at least one biocompatible base coat layer adhered to at least one surface of the material, and a thrombogenesis inhibitor immobilized on the base coat layer via a component capable of binding the inhibitor. The thrombogenesis inhibitor is hirudin, or an active analog or fragment thereof.

Abstract: Disclosed is a biocompatible, thromboresistant substance useful for implantable and extracorporeal devices in contact with the vascular system, and methods for producing the same. The biocompatible, thromboresistant substance comprises a synthetic, biocompatible material, at least one biocompatible base coat layer adhered to at least one surface of the material, and the thrombogenesis inhibitor thrombomodulin immobilized on the base coat layer via a component capable of binding the inhibitor without affecting its thrombogenesis-inhibiting activity.

Abstract: Novel aluminum and aluminum-zirconium salts are produced by reacting aluminum or aluminum-zirconium halohydrate with an anionic lipophilic component. These salts are useful in antiperspirant compositions or as rheological additives. Also disclosed is a novel process of producing oil-in-water emulsions whereby the novel aluminum or aluminum-zirconium salt functions as a surfactant upon forming.

Abstract: Retrovirally-infected cells are selectively killed as compared with uninfected cells using an effective amount of amino acid analogs of naturally occurring amino acids, such as L-canavanine (an analog of arginine).

Abstract: An improved method of producing a reservoir device having a rate-controlling membrane and zero-order (constant) release of an agent is provided. A core is sprayed with a solution having a polymer and a solvent, the solvent having a first component which is a rapidly evaporating, low-boiling-point first solvent and a slowly evaporating, high-boiling-point second solvent.

Abstract: Disclosed is an aerosol deodorant composition which includes an aerosol propellant, a volatile low-viscosity fluid, an oil absorbent particulate material, a silicone polymer and a deodorancy agent, such as at least one of a fragrance and a bactericide. The addition of the oil absorbent particulate material prevents dusting of liquid particles, and the addition of the silicone polymer prevents dusting by the oil absorbent particulate material. Also disclosed is an aerosol deodorant package including the aerosol deodorant composition and an aerosol delivery system having a valve which has orifices for passing the aerosol deodorant composition out of the package, the orifices having diameters such that the average delivery rate of the aerosol deodorant composition from the package is at most 0.44 gm/sec.

Abstract: The liposome compositions entrapping a drug are prepared by constituting the liposomal membrane with a saturated phospholipid and a glycolipid having sulfo group. Thus obtained compositions circulate stably in blood for a long time after intravenous administration.

Abstract: The present invention pertains to an edible coated composition which comprises (a) a core material comprising sorbitol, (b) a primary coating layer comprising zein over the core material, and (c) a sugarless secondary coasting layer over the primary coating layer. The present invention also pertains to methods for preparing the edible coated compositions.

Abstract: A process is provided for the condensation polymerizing lactic acid to a polymer with a weight average molecular weight of 2,500 to 4,500 containing less than 4% lactide and for a controlled release dosage form comprising a pharmaceutically active ingredient in a matrix of poly(lactic acid) and its copolymers with glycolic acid, valerolactone, .epsilon.-caprolactone, .epsilon.-decalactone, hydroxybutyric acid, .beta.-hydroxyvaleric acid and dioxanone.

Abstract: A pressed powder cosmetic product is disclosed. The product, useful as an eyeshadow, a blusher and the like, comprises a cream pressed powder composition and a frost pressed powder composition disposed adjacent to each other in the same pan. This unique arrangement is made possible by inclusion of surfactant coated fillers, surfactant coated colorants and a two component powder binder constituent.

Abstract: The present invention relates to an in vitro method for measuring the toxicity of a delta-endotoxin of Bacillus thuringiensis by evaluating the ability of said endotoxin to form an ion channel in a phospholipid vesicle.

Abstract: A composition for use an an insulin mimic comprising substances containing:a) vanadate; andb) peroxide.

Abstract: There are described novel dispersible cimetidine tablets containing 30 to 90% by weight of one of the polymorphous modifications of cimetidine A, B or C, 5 to 55% by weight of one or more disintegrationg agents, 0.05 to 5.0% by weight of a surfactant, such as sodium lauryl sulphate together with other common adjuvants. The process for the manufacture of dispersible cimetidine tablets is effected on the basis of known methods by granulating the ingredients and by compressing the granulate to tablets. Dispersible tablets disintegrate when brought in contact with water at room temperature within less than 1 minute to yield a fine dispersion, which facilitates the oral application. Therefore such tablets are particularly suitable for certain groups of patients, especially for the aged and children. Dispersible tablets containing cimetidine excell by their improved rate of dissolution and good bioavailability.